Last updated: August 9, 2026
Sodium thiosulfate is a low-cost inorganic pharmaceutical material with limited standalone excipient demand and materially greater value in regulated injectable drug products. The pharmaceutical opportunity is concentrated in high-purity sodium thiosulfate pentahydrate used in parenteral formulations, cyanide-antidote products, and sodium thiosulfate drug products such as PedMARK. Bulk demand remains exposed to industrial markets, especially water treatment, mining, metal processing, and photography.
The excipient market is fragmented, price-sensitive, and qualification-driven. Revenue growth is likely to come from regulatory-grade supply, sterile manufacturing support, and branded pharmaceutical applications rather than from large increases in excipient volume.
What is sodium thiosulfate used for in pharmaceutical products?
Sodium thiosulfate is used as an active pharmaceutical ingredient in several products and as a formulation component where its reducing, complexing, or sulfur-donating properties are required.
| Pharmaceutical use |
Product or setting |
Commercial relevance |
| Platinum-induced ototoxicity reduction |
PEDMARK, sodium thiosulfate injection |
Highest-value branded pharmaceutical application |
| Cyanide poisoning |
Sodium thiosulfate injection, usually with sodium nitrite in the U.S. |
Established emergency-use market |
| Calciphylaxis |
Intravenous or intralesional off-label use |
Hospital and specialty-compounding demand |
| Pharmaceutical excipient |
Formulation-specific use in finished products |
Smaller and less transparent market |
| Analytical and manufacturing reagent |
Pharmaceutical production and quality control |
Captive demand rather than finished-dose demand |
The distinction between excipient and active ingredient is commercially important. Sodium thiosulfate supplied for PEDMARK or cyanide-antidote injection is controlled as an API or drug-product component, not merely as a commodity excipient. FDA approved PEDMARK in September 2022 for reducing the risk of ototoxicity associated with cisplatin in pediatric patients with localized, nonmetastatic solid tumors.[1]
Sodium thiosulfate is generally supplied as sodium thiosulfate pentahydrate, with the chemical formula Na2S2O3·5H2O and CAS number 10102-17-7. Anhydrous sodium thiosulfate has CAS number 7772-98-7. The hydrate state affects assay calculation, water content, stability, and formulation performance.
How large is the pharmaceutical sodium thiosulfate market?
No authoritative public dataset isolates pharmaceutical excipient revenue for sodium thiosulfate. Commercial market reports that publish a “sodium thiosulfate market” figure generally combine pharmaceutical, industrial, water-treatment, mining, photographic, and other uses. Those estimates cannot be used to value the pharmaceutical excipient segment without a bottom-up adjustment.
The pharmaceutical segment is best understood as a small specialty submarket within a much larger inorganic chemical category.
Market structure by value driver
| Value driver |
Effect on sodium thiosulfate demand |
| Industrial production capacity |
Keeps bulk pricing low |
| Pharmaceutical-grade purification |
Raises price per kilogram |
| Sterile filling capability |
Creates the largest value uplift |
| Regulatory qualification |
Increases switching costs |
| Pediatric oncology demand |
Supports PEDMARK volumes |
| Cyanide antidote procurement |
Produces episodic institutional demand |
| Compounding demand |
Adds fragmented hospital demand |
| Water treatment and mining cycles |
Can affect upstream availability and pricing |
Pharmaceutical demand is unlikely to determine global sodium thiosulfate production economics. Industrial demand generally has greater influence over manufacturing scale, raw-material procurement, and base pricing. Pharmaceutical buyers therefore benefit from a relatively broad chemical supply base but must qualify suppliers for impurity control, microbiological quality, packaging, traceability, and change-control performance.
What are the main growth drivers for pharmaceutical sodium thiosulfate?
The strongest growth drivers are regulated drug products, not conventional excipient substitution.
PEDMARK commercialization
PEDMARK created a dedicated U.S. commercial market for pharmaceutical-grade sodium thiosulfate. Its use is tied to pediatric cisplatin treatment, oncology-center adoption, reimbursement, treatment protocols, and physician familiarity. The product is supplied as an intravenous formulation and is administered after cisplatin under the approved dosing regimen.[1]
PEDMARK demand can increase the value of qualified sodium thiosulfate supply even when absolute kilogram consumption remains modest. A branded injectable manufacturer requires more than chemical identity. It needs validated specifications, stable supply, documented manufacturing controls, and a supplier capable of supporting regulatory filings.
Cyanide-antidote procurement
Sodium thiosulfate injection is an established treatment component for cyanide poisoning. Procurement is concentrated among hospitals, emergency departments, government agencies, industrial employers, and emergency-response stockpiles. Demand is irregular and tender-driven.
The market has lower brand loyalty than pediatric oncology but may carry supply premiums during shortages or government procurement cycles. Product availability depends on sterile injectable manufacturing capacity, not only on sodium thiosulfate powder production.
Hospital compounding and off-label use
Intravenous sodium thiosulfate has been used off-label for calciphylaxis, a serious condition associated with chronic kidney disease. This demand is fragmented across hospitals and compounding pharmacies. It can support specialty-grade sales but does not provide the predictable volume profile of a widely adopted approved indication.
How does the sodium thiosulfate supply chain work?
The supply chain has four commercial layers:
- Production of sodium thiosulfate from sulfur-containing feedstocks and sodium compounds.
- Purification, crystallization, and control of hydrate state.
- Pharmaceutical qualification, packaging, and release testing.
- Sterile formulation and finished-dose manufacture.
The most important quality attributes include assay, identity, water content, insoluble matter, sulfite and sulfate impurities, heavy metals, elemental impurities, bioburden, endotoxin where applicable, and container-closure compatibility.
Manufacturing and intellectual-property barriers
The chemical itself is old and widely known. Manufacturing know-how can still create practical barriers through:
- Consistent control of crystallization and hydration;
- Low impurity profiles;
- Control of oxidation and decomposition pathways;
- Reliable pharmaceutical-grade documentation;
- Validated sterilization or aseptic-processing support;
- Batch-to-batch consistency;
- Audit readiness and change-control discipline.
These barriers are operational rather than fundamental patent barriers. A supplier may be technically capable of producing sodium thiosulfate but still fail to qualify for an injectable pharmaceutical application.
What is the FDA regulatory status of sodium thiosulfate?
Sodium thiosulfate has multiple regulatory identities. It can be an active ingredient in an approved drug, a component of a compounded preparation, or an excipient in a formulation-specific product.
FDA approval of PEDMARK applies to the finished drug and its labeled use, not to sodium thiosulfate as a universally interchangeable pharmaceutical ingredient.[1] Each manufacturer remains responsible for the quality, specifications, manufacturing process, and regulatory status of its product.
The FDA Inactive Ingredient Database is relevant only where sodium thiosulfate is used as an inactive ingredient in a specific approved dosage form and route. Presence in the database does not create general approval for every route, concentration, or formulation.[2]
For pharmaceutical use, buyers normally require compliance with applicable United States Pharmacopeia-National Formulary standards where cited by the product specification, together with current good manufacturing practice controls. API suppliers may also be evaluated under ICH Q7 principles when the material is used as an active pharmaceutical ingredient or as a critical drug-substance input.[3]
What patents protect sodium thiosulfate pharmaceutical products?
The sodium thiosulfate molecule itself is not protected by a modern composition-of-matter patent. Its chemical identity and core uses have been known for many decades.
Patent exposure is concentrated in:
- Specific pharmaceutical formulations;
- Dosing regimens;
- Treatment methods;
- Combination therapy with cisplatin;
- Pediatric oncology use;
- Stability and packaging systems;
- Manufacturing or purification processes.
For PEDMARK, the commercial protection strategy is product- and use-specific. Patent rights must be assessed against the current FDA Orange Book listings, issued patents, expiration dates, pediatric exclusivity, and any patent-term adjustment.[4]
Orange Book and Paragraph IV risk
An abbreviated new drug application applicant may challenge listed patents through a Paragraph IV certification. The risk depends on whether a generic applicant can design around formulation and method-of-use claims or can lawfully omit protected indications through a section viii statement.
The principal generic-entry risks are:
| Risk area |
Assessment |
| Active-ingredient substitution |
High feasibility because sodium thiosulfate is an old compound |
| Formulation design-around |
Potentially feasible, depending on claims |
| Injectable equivalence |
More difficult than oral solid-dose substitution |
| Method-of-use protection |
Important for pediatric cisplatin use |
| Manufacturing qualification |
Significant practical barrier |
| Paragraph IV litigation |
Product-specific and dependent on listed patents |
| Biosimilar risk |
Not applicable to sodium thiosulfate |
Biosimilar competition is irrelevant because sodium thiosulfate is a small-molecule chemical, not a biologic. Competition would arise through generic injectable products, alternative suppliers, hospital compounding, or competing otoprotection strategies.
When does sodium thiosulfate lose exclusivity?
Sodium thiosulfate itself has no meaningful molecule-level exclusivity period. Exclusivity applies to a particular finished drug, indication, formulation, or patent estate.
PEDMARK received FDA approval in 2022. Its effective market protection depends on the combination of regulatory exclusivity, listed patents, pediatric exclusivity, formulation claims, method-of-use claims, and the timing of any approved generic application.[1][4]
A precise generic-entry date cannot be assigned from the chemical identity alone. The relevant date is the latest enforceable barrier affecting the proposed generic product, subject to litigation, settlement terms, patent-term adjustments, pediatric exclusivity, and FDA approval timing.
Which companies compete in pharmaceutical sodium thiosulfate?
Competition exists at several levels rather than through a single branded market.
Finished pharmaceutical products
Fennec Pharmaceuticals commercializes PEDMARK in the United States. Sodium thiosulfate injection products for cyanide poisoning are supplied through established generic and emergency-medicine channels. Hospital pharmacies and outsourcing facilities may supply compounded sodium thiosulfate preparations for off-label use.
Excipient and API suppliers
Potential suppliers include large pharmaceutical-material distributors, compounding suppliers, laboratory-chemical manufacturers, and specialized API producers. The competitive set varies by geography and by whether the buyer requires:
- USP/NF or equivalent compendial quality;
- GMP manufacturing;
- DMF or regulatory-support documentation;
- Sterile or nonsterile material;
- Small commercial quantities or high-volume supply;
- Global audit and change-notification systems.
Supplier qualification can last months or longer because a change in source may require comparability testing, stability work, regulatory notification, or a supplement to an approved application.
What is the financial trajectory for sodium thiosulfate?
The financial trajectory is bifurcated.
Bulk excipient economics
Bulk sodium thiosulfate is a low-margin chemical product. Pricing is driven by production cost, sulfur and sodium inputs, energy, freight, crystallization yield, packaging, and regional supply-demand balance. Pharmaceutical-grade premiums improve gross margin but usually do not transform the product into a high-value specialty excipient.
Revenue growth in this segment is likely to track:
- Expansion of injectable and specialty pharmaceutical production;
- Increased regulatory sourcing requirements;
- Supplier consolidation;
- Demand for documented GMP material;
- Regionalization of pharmaceutical supply chains.
Finished-drug economics
Finished PEDMARK and other injectable products have much higher value per kilogram because pricing reflects clinical utility, regulatory approval, sterile manufacturing, distribution, reimbursement, and market access. A small amount of sodium thiosulfate can support a substantially larger finished-product revenue stream.
Fennec Pharmaceuticals’ public filings report company-level commercial performance for PEDMARK, but they do not establish a transparent global revenue pool for sodium thiosulfate excipient sales.[5] Investors should therefore avoid applying branded-drug revenue multiples to the underlying excipient market.
Scenario framework
| Scenario |
Excipient impact |
Finished-drug impact |
| Base case |
Low-to-moderate growth, stable commodity pricing |
Gradual PEDMARK adoption and institutional demand |
| Upside case |
More qualified suppliers and broader injectable use |
Higher pediatric oncology penetration and expanded use |
| Downside case |
Price pressure and substitution among suppliers |
Generic entry, reimbursement pressure, or slower adoption |
| Supply disruption |
Temporary price increase and qualification stress |
Potential injectable shortages and inventory buildup |
The most attractive financial position is generally upstream of a regulated finished product: a qualified supplier with long-term contracts, validated specifications, and low switching probability. Spot-market sales of commodity-grade sodium thiosulfate offer less defensible economics.
How strong is the sodium thiosulfate pharmaceutical patent estate?
The estate is weak at the molecule level and potentially meaningful at the product level.
| Protection layer |
Strength |
| Sodium thiosulfate composition of matter |
None of practical commercial significance |
| Basic chemical manufacturing |
Generally weak or expired |
| Pharmaceutical formulation |
Moderate if claims are narrow and difficult to design around |
| Pediatric cisplatin method of use |
Potentially meaningful |
| Sterile injectable presentation |
Depends on claim scope and approval pathway |
| Supplier manufacturing know-how |
Contractual and operational, not necessarily patent-based |
| Biosimilar protection |
Not applicable |
Commercial durability depends more on clinical adoption, FDA labeling, institutional protocols, manufacturing controls, and reimbursement than on exclusivity for the chemical itself.
What generic launch scenarios exist for sodium thiosulfate products?
Three scenarios are commercially plausible:
- A generic injectable targets the cyanide-antidote market, where the product has an established clinical role and pricing is likely competitive.
- A generic or follow-on product targets the PEDMARK market after resolving listed-patent and regulatory barriers.
- Hospitals and compounding pharmacies continue to supply lower-cost alternatives for off-label use, limiting the addressable premium market.
A generic injectable may face lower development complexity than a novel drug but greater operational complexity than a standard oral generic. Sterility assurance, container compatibility, stability, extractables and leachables, and supply continuity become critical.
Key Takeaways
- Sodium thiosulfate is a commodity-scale inorganic chemical but a specialty material in regulated pharmaceutical supply.
- The pharmaceutical excipient market is smaller and less transparent than broad sodium thiosulfate market estimates suggest.
- PEDMARK is the main high-value branded application, while cyanide-antidote products provide established emergency-use demand.
- The chemical has no meaningful modern composition-of-matter exclusivity.
- Product-level patents, method-of-use claims, regulatory exclusivity, and sterile-manufacturing requirements determine generic risk.
- Biosimilar competition does not apply.
- Bulk excipient economics are low-margin and supply-driven; finished-drug economics are driven by clinical adoption and regulatory barriers.
- The strongest supplier position is a qualified GMP source integrated into an approved injectable product.
FAQs About the Sodium Thiosulfate Pharmaceutical Market
Is sodium thiosulfate an API or an excipient?
It can be either. In PEDMARK and cyanide-antidote injections, it is the active pharmaceutical ingredient. In another formulation, it may be used as an inactive component if supported by the product’s regulatory filing and applicable dosage-form requirements.
Does sodium thiosulfate have USP status?
Pharmaceutical buyers may specify USP/NF-grade sodium thiosulfate, but the applicable monograph, hydrate state, assay basis, and testing requirements must be confirmed against the purchasing specification and finished-product application.
Can sodium thiosulfate be replaced by another excipient?
Replacement depends on its function. If it provides a specific reducing, sulfur-donating, or complexing effect, substitution requires formulation development, compatibility testing, stability data, and regulatory assessment.
Is pharmaceutical sodium thiosulfate subject to drug shortages?
The chemical itself may remain available while sterile injectable products experience shortages. The principal bottleneck is often aseptic filling, packaging, quality release, or limited qualified capacity rather than bulk chemical synthesis.
What is the investment risk in sodium thiosulfate suppliers?
The main risks are commodity pricing, limited pharmaceutical volume, customer concentration, qualification delays, regulatory noncompliance, and dependence on one sterile manufacturing or API source. The strongest opportunities involve long-term supply agreements tied to approved injectable products.
References
- U.S. Food and Drug Administration. (2022). PEDMARK (sodium thiosulfate) injection, prescribing information.
- U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
- International Council for Harmonisation. (2000). ICH Q7: Good manufacturing practice guide for active pharmaceutical ingredients.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Fennec Pharmaceuticals, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023.
- United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
